Pathological and Immunological Developments in Behcet’s DiseaseView this Special Issue
Review Article | Open Access
Massimiliano Galeone, Roberta Colucci, Angelo Massimiliano D'Erme, Silvia Moretti, Torello Lotti, "Potential Infectious Etiology of Behçet's Disease", Pathology Research International, vol. 2012, Article ID 595380, 4 pages, 2012. https://doi.org/10.1155/2012/595380
Potential Infectious Etiology of Behçet's Disease
Behçet's disease is a multisystem inflammatory disorder characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. The cause of Behçet's disease remains unknown, but epidemiologic findings suggest that an autoimmune process is triggered by an environmental agent in a genetically predisposed individual. An infectious agent could operate through molecular mimicry, and subsequently the disease could be perpetuated by an abnormal immune response to an autoantigen in the absence of ongoing infection. Potentia bacterial are Saccharomyces cerevisiae, mycobacteria, Borrelia burgdorferi, Helicobacter pylori, Escherichia coli, Staphylococcus aureus, and Mycoplasma fermentans, but the most commonly investigated microorganism is Streptococcus sanguinis. The relationship between streptococcal infections and Behçet's disease is suggested by clinical observations that an unhygienic oral condition is frequently noted in the oral cavity of Behçet's disease patients. Several viral agents, including herpes simplex virus-1, hepatitis C virus, parvovirus B19, cytomegalovirus, Epstein-Barr virus and varicella zoster virus, may also have some role.
Behçet’s disease is a multisystem inflammatory disorder characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions and generally presents with remissions and exacerbations. It can frequently involve the joints, gastrointestinal tract, and central nervous system [1, 2].
Behçet’s disease is most prevalent along the “Silk Road,” an ancient trading route between the Mediterranean and East Asia, where it is a major cause of morbidity. In Turkey, the country with the highest incidence of the disease, the prevalence is estimated to be between 110 and 420 per 100.000, whereas that in Japan is 13–20 per 100.000, and the prevalence in the UK and USA is estimated at 1-2 per 100.000. The typical age of onset is in the third or fourth decade of life and the male-to-female ratio varies with ethnic origin [1, 3, 4].
The study of migrant populations led to interesting epidemiological findings. Individuals from endemic areas who have immigrated to areas with low prevalence of the disease have an intermediate risk for developing the disease, which points that environment has some role in Behçet’s disease. Turkish individuals who have emigrated to Germany have a significantly lower risk of disease than individuals of Turkish origin living in Turkey, although their risk remains higher than that of the native German population. Similarly, the disease is virtually unknown in Japanese immigrants to Hawaii, mainland USA, or South America despite a high prevalence in Japan [5, 6].
The cause of Behçet’s disease remains unknown, but epidemiologic findings suggest that an autoimmune process is triggered by an infectious or environmental agent (possibly local to a geographic region) in a genetically predisposed individual [7, 8]. Whatever the stimulus is, the target tissue seems to be the small blood vessels, with various consequences of either vasculitis and/or thrombosis in many organ systems .
The genetic susceptibility is strongly associated with the presence of the HLA-B51 allele, with a stronger association in Turkish and Japanese patients in comparison to Caucasians. The unusual geographic distribution of Behçet’s disease and its close association with HLA-B51 may be the strongest indicator that certain genes are directly responsible for Behçet’s disease or of indirectly promoting the characteristics of the underlying inflammatory changes. Other genes located outside the HLA region have been also proposed, including genes of coagulation factor V, intercellular adhesion molecule-1 (ICAM-1), and endothelial nitric oxide synthetase [10–12].
As is the case of other autoimmune diseases, there is interest in an infectious etiology. Although there is no information supporting the role of a single microorganism as the specific cause, a problem with dysregulation in innate immunity, with an altered response to more than one infectious agent, is a generally accepted theory. An infectious agent could operate through molecular mimicry. This mimicked interaction or false signalling could attract the inflammatory cells into the field of action, and this may in turn result in vasculitis. Subsequently, the disease could be perpetuated by an abnormal immune response to an autoantigen in the absence of ongoing infection .
A viral cause was first postulated by Behçet in 1937 . Evidence of ongoing infection with a variety of viral agents has been sought. However, often there is only a history of previous infection and/or seropositivity . Although herpetiform ulcers are unusual, herpes simplex virus-1 (HSV-1) is currently the most common virus associated with Behçet’s disease. HSV DNA and serum antibodies against the virus have been found in a higher proportion of patients with Behçet’s disease than in controls, and circulating immune complexes with the HSV-1 antigen have been reported. HSV DNA has been demonstrated in the genital and intestinal ulcers, but not in oral ulcers. However, anti-HSV immunity is also common in normal subjects, and results about therapeutic effects of antiviral treatment in Behçet’s disease are scarce and controversial [15, 16]. Several other viral agents, including hepatitis C virus, parvovirus B19, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus, may also have some role [17–21].
Potential bacteria are a variety of streptococcal antigens, Saccharomyces cerevisiae, mycobacteria, Borrelia burgdorferi, Helicobacter pylori, Escherichia coli, Staphylococcus aureus, Mycoplasma fermentans [22–27]. The infectious model is also supported by observations that oral ulcers precede the establishment of disease by months or years and disease relapses are frequent. Thus, oral microbial flora have long been implicated in the pathogenesis. The most commonly investigated microorganism is Streptococcus. The relationship between streptococcal infections and Behçet’s disease is suggested by clinical observations that an unhygienic oral condition including periodontitis, decayed teeth, and chronic tonsillitis is frequently noted in the oral cavity of Bechet’s disease patients . It is not clear that the predisposition of the patients is correlated with streptococcal infection, but the uncommon oral Streptococcus sanguinis serotypes (called KTH-1) and antibodies against the bacteria are significantly increased in the oral flora and serum, respectively, of patients with the disease compared with healthy controls . The patients show strong delayed-type cutaneous hypersensitivity reactions against streptococcal antigens in skin tests and sometimes Behçet’s disease symptoms were provoked by skin injection of the antigens . The new criteria included hypersensitivity skin reactions against streptococci in the diagnosis as one of the references and the levels of disease severity of Behçet’s disease patients . S. sanguinis antigens share a sequence of amino acids with one of the protein classes of the cellular membranes called heat shock proteins (HSPs), which are expressed above the cellular membrane in response to physiological shocks and microbial stimulus . Thus, HSPs are possible candidate antigen for Behçet’s disease. Particularly, the peptides of 65 kDa (HSP-65) derived from the bacteria show considerable homology with those of the human 60 kDa (HSP-60). Moreover, mycobacterial and human HSPs have over 50% in sequence homology . Studies have shown that S. sanguis and HSP 60/65 kDa activate T cells in Behçet’s disease patients but not controls. It is suggested that, following the bacterial stimulus, mucous cells express HSPs which are antigenic and reactive antimucous T cells in susceptible individuals (molecular mimicry model) . As for the most other autoimmune disorders, the Th1-type polarization is predominant in Behçet’s disease . T lymphocytes have a role in the immune response to infections and in autoimmunity by recognizing bacteria-derived and autologous antigens. Patients with Behçet’s disease have increased numbers of activated T cells (in circulation and in mucosal lesions), which produce inflammatory cytokines, including IFN-, TNF-, and IL-8. Culture of T lymphocytes from Behçet’s disease patients proliferates in response to mycobacterial HSP-derived peptides and in response to products from microorganisms in oral ulcers [11, 33]. Complex interactions between T cells, antigen presenting cells, (APCs) and neutrophils are involved in the immune pathogenesis of Behçet’s disease. Neutrophils are hyperactive in Behçet’s disease, with increased chemotaxis, phagocytosis, superoxide production and myeloperoxidase expression and produce several cytokines . Behçet’s disease lesions might be induced with vascular reaction or lymphocytic vasculitis as the immunological reaction by the APCs expressing the S. sanguinis antigens . Moreover, the amino acid sequence of the peptides of Bes-1, a gene derived from oral S. sanguinis, shows more than 60% similarity to the human intraocular ganglion peptide, Brn-3b. These results suggest that Bes-1 might be an inducer for the retinal and neural involvement possible in Behçet’s disease patients .
Pustular skin lesions are often not sterile and may contain Staphylococcus aureus and Prevotella species. Whether these pustules are secondarily infected or whether the infections play a pathogenic role in the development of pustular lesions remains to be determined .
Anti-S. cerevisiae antibodies (ASCAs) may be especially common in intestinal Beçhet’s disease and are also increased in healthy relatives of patients, according to the study by Choi et al. who evaluated whether ASCA expression is associated with clinical findings at diagnosis and the clinical course of intestinal Behçet’s disease and found that the ASCA-positive rate was 44.3% in intestinal Behçet’s disease but was not related to clinical findings at diagnosis and cumulative relapse rates .
4. Therapeutic Implications
Antiseptic agents and antibiotics are used to control microbial contamination and secondary infection . Chlorhexidine gel and triclosan have been shown to reduce the number, pain severity, and duration of aphthous ulcers [40, 41].
Antibiotics, especially tetracycline, has been widely used in oral ulcers of Behçet’s disease for years. Tetracycline mouthwash decreases pain severity and duration of oral ulcers. Minocycline mouthwashes as compared to topical tetracycline rinses resulted in significantly improved pain control, by reducing the severity and duration of pain . Minocycline reduces not only the growth of oral streptococci, but also suppresses interleukins production from T cells . The effect of penicillin on mucocutaneous lesions and arthritis has been examined in two different studies, and it was found that prophylactic penicillin treatment reduced both the mucocutaneous lesions and the arthritis episodes. Other studies also showed that combination therapy, 1200000 units of benzathine-penicillin injected monthly plus 1 mg of oral colchicine daily for 4 months, was effective to suppress Behçet’s disease symptoms, compared to colchicine monotherapy [44–46].
Acyclovir is not effective in the treatment of oral and genital ulceration .
The role of microorganisms in the pathogenesis of Behçet’s disease has long been investigated, and there are ample data on several microorganisms. However, none of these infectious agents have been proved to cause Behçet’s disease. Thus, a complex immune response might be generated to a group of microorganisms that share common antigens rather than to an infection due to a specific single microorganism.
The authors confirm that the paper is an original work and that it has not been published and is not under consideration elsewhere.
All of the authors participated in the preparation of the paper.
Conflict of Interests
The authors have no financial obligations or conflict of interests to declare.
- T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, “Behçet's disease,” New England Journal of Medicine, vol. 341, no. 17, pp. 1284–1291, 1999.
- S. E. Marshall, “Behçet's disease,” Best Practice and Research: Clinical Rheumatology, vol. 18, no. 3, pp. 291–311, 2004.
- A. Idil, A. Gürler, A. Boyvat et al., “The prevalence of Behçet's disease above the age of 10 years: the results of a pilot study conducted at the park primary health care center in Ankara, Turkey,” Ophthalmic Epidemiology, vol. 9, no. 5, pp. 325–331, 2002.
- G. Azizlerli, A. A. Köse, R. Sarica et al., “Prevalence of Behçet's disease in Istanbul, Turkey,” International Journal of Dermatology, vol. 42, no. 10, pp. 803–806, 2003.
- C. C. Zouboulis, I. Kötter, D. Djawari et al., “Epidemiological features of adamantiades-Behçet's disease in Germany and in Europe,” Yonsei Medical Journal, vol. 38, no. 6, pp. 411–422, 1997.
- T. Hirohata, M. Kuratsune, A. Nomura, and S. Jimi, “Prevalence of Behcet's syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan,” Hawaii Medical Journal, vol. 34, no. 6, pp. 244–246, 1975.
- S. Pay, I. Şimşek, H. Erdem, and A. Dinç, “Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells,” Rheumatology International, vol. 27, no. 5, pp. 417–424, 2007.
- A. Kulaber, I. Tugal-Tutkun, P. Sibel et al., “Pro-inflammatory cellular immune response in Behçet's disease,” Rheumatology International, vol. 27, no. 12, pp. 1113–1118, 2007.
- A. Kalayciyan and C. C. Zouboulis, “An update on Behçet's disease,” Journal of the European Academy of Dermatology and Venereology, vol. 21, no. 1, pp. 1–10, 2007.
- D. H. Verity, J. E. Marr, S. Ohno, G. R. Wallace, and M. R. Stanford, “Behçet's disease, the silk road and HLA-B51: historical and geographical perspectives,” Tissue Antigens, vol. 54, no. 3, pp. 213–220, 1999.
- D. Mendes, M. Correia, M. Barbedo et al., “Behçet's disease—a contemporary review,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 178–188, 2009.
- C. Mendoza-Pinto, M. García-Carrasco, M. Jiménez-Hernández et al., “Etiopathogenesis of Behcet's disease,” Autoimmunity Reviews, vol. 9, no. 4, pp. 241–245, 2010.
- S. Yurdakul and H. Yazici, “Behçet's syndrome,” Best Practice and Research: Clinical Rheumatology, vol. 22, no. 5, pp. 793–809, 2008.
- H. Behcet, “Uber rezidivierende, aphthous durch ein virus verursachte geschwure am mund, am auge und an den genitalien,” Dermatol Wochenschri, vol. 105, pp. 1152–1157, 1937.
- H. Direskeneli, “Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51,” Annals of the Rheumatic Diseases, vol. 60, no. 11, pp. 996–1002, 2001.
- V. G. Kaklamani, G. Vaiopoulos, and P. G. Kaklamanis, “Behcet's disease,” Seminars in Arthritis and Rheumatism, vol. 27, no. 4, pp. 197–217, 1998.
- N. Ilter, E. Senol, M. A. Gürer, and M. O. Oztaş, “Behcet's disease and HCV infection,” International Journal of Dermatology, vol. 39, no. 5, pp. 396–397, 2000.
- S. Kiraz, M. A. Oztürk, I. Ertenli, and M. Calgüneri, “Parvovirus B19 infection in Behçet's disease,” Annals of the Rheumatic Diseases, vol. 60, no. 8, pp. 814–815, 2001.
- A. Sun, J. G. Chang, C. L. Kao et al., “Human cytomegalovirus as a potential etiologic agent in recurrent aphthous ulcers and Behçet's disease,” Journal of Oral Pathology and Medicine, vol. 25, no. 5, pp. 212–218, 1996.
- A. Sun, J. G. Chang, C. T. Chu, B. Y. Liu, J. H. Yuan, and C. P. Chiang, “Preliminary evidence for an association of Epstein-Barr virus with pre-ulcerative oral lesions in patients with recurrent aphthous ulcers or Behcet's disease,” Journal of Oral Pathology and Medicine, vol. 27, no. 4, pp. 168–175, 1998.
- S. Akdeniz, M. Harman, S. Atmaca, and N. Akpolat, “The seroprevalence of varicella zoster antibodies in Behçet's and other skin diseases,” European Journal of Epidemiology, vol. 18, no. 1, pp. 91–93, 2003.
- T. Lehner, E. Lavery, R. Smith, R. van der Zee, Y. Mizushima, and T. Shinnick, “Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome,” Infection and Immunity, vol. 59, no. 4, pp. 1434–1441, 1991.
- I. Krause, Y. Monselise, G. Milo, and A. Weinberger, “Anti-saccharomyces cerevisiae antibodies—a novel serologic marker for Behçet's disease,” Clinical and Experimental Rheumatology, vol. 20, no. 4, pp. S21–S24, 2002.
- E. Isogai, H. Isogai, S. Kotake et al., “Detection of antibodies against Borrelia burgdorferi in patients with uveitis,” American Journal of Ophthalmology, vol. 112, no. 1, pp. 23–30, 1991.
- O. Avci, E. Ellidokuz, I. Simşek, B. Büyükgebiz, and A. T. Güneş, “Helicobacter pylori and Behçet's disease,” Dermatology, vol. 199, no. 2, pp. 140–143, 1999.
- Z. Amoura, M. Guillaume, S. Caillat-Zucman, B. Wechsler, and J. C. Piette, “Pathophysiology of Behçet's disease,” La Revue de Médecine Interne, vol. 27, no. 11, pp. 843–853, 2006.
- C. C. Zouboulis, J. R. Turnbull, and P. F. Mühlradt, “Association of mycoplasma fermentans with adamantiades-Behçet's disease,” Advances in experimental medicine and biology, vol. 528, pp. 191–194, 2003.
- G. Mumcu, N. Inanc, S. Yavuz, and H. Direskeneli, “The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease,” Clinical and Experimental Rheumatology, vol. 25, supplement 45, no. 4, pp. S27–S33, 2007.
- K. Yoshikawa, S. Kotake, Y. Sasamoto, S. Ohno, and H. Matsuda, “Close association of Streptococcus sanguis and Behçet's disease,” Nihon Ganka Gakkai Zasshi, vol. 95, no. 12, pp. 1261–1267, 1991.
- F. Kaneko, N. Oyama, H. Yanagihori, E. Isogai, K. Yokota, and K. Oguma, “The role of streptococcal hypersensitivity in the pathogenesis of Behçet's disease,” European Journal of Dermatology, vol. 18, no. 5, pp. 489–498, 2008.
- M. S. Kurokawa and N. Suzuki, “Behçet's disease,” Clinical and Experimental Medicine, vol. 4, no. 1, pp. 10–20, 2004.
- T. Lehner, “The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease,” International Reviews of Immunology, vol. 14, no. 1, pp. 21–32, 1997.
- I. Bank, M. Duvdevani, and A. Livneh, “Expansion of γδ T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers,” Journal of Laboratory and Clinical Medicine, vol. 141, no. 1, pp. 33–40, 2003.
- M. Zierhut, N. Mizuki, S. Ohno et al., “Immunology and functional genomics of Behçet's disease,” Cellular and Molecular Life Sciences, vol. 60, no. 9, pp. 1903–1922, 2003.
- M. Xiang, L. Zhou, Y. W. Peng, R. L. Eddy, T. B. Shows, and J. Nathans, “Brn-3b: a POU domain gene expressed in a subset of retinal ganglion cells,” Neuron, vol. 11, no. 4, pp. 689–701, 1993.
- G. Hatemi, H. Bahar, S. Uysal et al., “The pustular skin lesions in Behçet's syndrome are not sterile,” Annals of the Rheumatic Diseases, vol. 63, no. 11, pp. 1450–1452, 2004.
- C. H. Choi, T. I. Kim, B. C. Kim et al., “Anti-saccharomyces cerevisiae antibody in intestinal Behçet's disease patients: relation to clinical course,” Diseases of the Colon and Rectum, vol. 49, no. 12, pp. 1849–1859, 2006.
- E. Jacobs, A. Bartl, K. Oberle, and E. Schiltz, “Molecular mimicry by Mycoplasma pneumoniae to evade the induction of adherence inhibiting antibodies,” Journal of Medical Microbiology, vol. 43, no. 6, pp. 422–429, 1995.
- E. Alpsoy, “Behçet's disease: treatment of mucocutaneous lesions,” Clinical and Experimental Rheumatology, vol. 23, no. 4, pp. 532–539, 2005.
- A. B. Skaare, B. B. Herlofson, and P. Barkvoll, “Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU),” Journal of Clinical Periodontology, vol. 23, no. 8, pp. 778–781, 1996.
- E. Alpsoy and A. Akman, “Behçet's disease: an algorithmic approach to its treatment,” Archives of Dermatological Research, vol. 301, no. 10, pp. 693–702, 2009.
- M. Gorsky, J. B. Epstein, S. Rabenstein, H. Elishoov, and N. Yarom, “Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study,” Dermatology Online Journal, vol. 13, no. 2, p. 1, 2007.
- F. Kaneko, N. Oyama, and A. Nishibu, “Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms,” Yonsei Medical Journal, vol. 38, no. 6, pp. 444–454, 1997.
- M. Calgüneri, S. Kiraz, I. Ertenli, M. Benekli, Y. Karaarslan, and I. Çelik, “The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease: a randomized clinical trial,” Arthritis and Rheumatism, vol. 39, no. 12, pp. 2062–2065, 1996.
- M. Çalgüneri, I. Ertenli, S. Kiraz, M. Erman, and I. Çelik, “Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease,” Dermatology, vol. 192, no. 2, pp. 125–128, 1996.
- M. M. Al-Waiz, K. E. Sharquie, M. H. A-Qaissi, and R. K. Hayani, “Colchicine and benzathine penicillin in the treatment of Behçet disease: a case comparative study,” Dermatology Online Journal, vol. 11, no. 3, p. 3, 2005.
- U. M. Davies, R. G. Palmer, and A. M. Denman, “Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome: a randomized double-blind trial,” British Journal of Rheumatology, vol. 27, no. 4, pp. 300–302, 1988.
Copyright © 2012 Massimiliano Galeone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.